Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Ragothaman Srinivasan

Phio Pharmaceuticals Open enrollment in Phase 1b Trial of PH-762 for the Treatment of Advanced Melanoma

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) has started enrolling patients in the Phase 1b clinical trial of PH-762 for the treatment of advanced melanoma.

The phase 1b study will evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of PH-762 in a neoadjuvant setting in subjects with advanced melanoma.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.